Literature DB >> 20686639

HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb.

Rameshwer Shukla1, Thommey P Thomas, Ankur M Desai, Alina Kotlyar, Steve J Park, James R Baker.   

Abstract

Herceptin, a humanized monoclonal antibody that binds to human growth factor receptor-2 (HER2), was covalently attached to a fifth-generation (G5) polyamidoamine dendrimer containing the cytotoxic drug methotrexate. The specific binding and internalization of this conjugate labeled with FITC was clearly demonstrated in cell lines overexpressing HER2 by flow cytometry as well as confocal microscopic analysis. In addition, binding and uptake of antibody conjugated dendrimers was completely blocked by excess non-conjugated herceptin. The dendrimer conjugate was also shown to inhibit the dihydrofolate reductase with similar activity to methotrexate. Co-localization experiments with lysotracker red indicate that antibody conjugate, although internalized efficiently into cells, has an unusually long residence time in the lysosome. Somewhat lower cytotoxicity of the conjugate in comparison to free methotrexate was attributed to the slow release of methotrexate from the conjugate and its long retention in the lysosomal pocket.

Entities:  

Keywords:  Antibody; Conjugate; Dendrimer; Drug delivery; Herceptin; Methotrexate

Year:  2008        PMID: 20686639      PMCID: PMC2913620          DOI: 10.1088/0957-4484/19/29/295102

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  20 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

Authors:  Anil K Patri; Andrzej Myc; James Beals; Thommey P Thomas; Neil H Bander; James R Baker
Journal:  Bioconjug Chem       Date:  2004 Nov-Dec       Impact factor: 4.774

3.  Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.

Authors:  Gong Wu; Rolf F Barth; Weilian Yang; Shinji Kawabata; Liwen Zhang; Kari Green-Church
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

4.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.

Authors:  Jolanta F Kukowska-Latallo; Kimberly A Candido; Zhengyi Cao; Shraddha S Nigavekar; Istvan J Majoros; Thommey P Thomas; Lajos P Balogh; Mohamed K Khan; James R Baker
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

5.  Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy.

Authors:  István J Majoros; Thommey P Thomas; Chandan B Mehta; James R Baker
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

6.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

7.  Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.

Authors:  Heidrun Wartlick; Kerstin Michaelis; Sabine Balthasar; Klaus Strebhardt; Jörg Kreuter; Klaus Langer
Journal:  J Drug Target       Date:  2004       Impact factor: 5.121

8.  Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography.

Authors:  John A Copland; Mohammad Eghtedari; Vsevolod L Popov; Nicholas Kotov; Natasha Mamedova; Massoud Motamedi; Alexander A Oraevsky
Journal:  Mol Imaging Biol       Date:  2004 Sep-Oct       Impact factor: 3.488

9.  Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.

Authors:  Shih-Jiuan Chiu; Naoto T Ueno; Robert J Lee
Journal:  J Control Release       Date:  2004-06-18       Impact factor: 9.776

10.  Assay for expression of methotrexate-resistant dihydrofolate reductase activity in the presence of drug-sensitive enzyme.

Authors:  K Thompson; D B Vinh; R S McIvor
Journal:  J Pharmacol Toxicol Methods       Date:  1992-11       Impact factor: 1.950

View more
  19 in total

1.  Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.

Authors:  Ming-Hsin Li; Seok Ki Choi; Thommey P Thomas; Ankur Desai; Kyung-Hoon Lee; Alina Kotlyar; Mark M Banaszak Holl; James R Baker
Journal:  Eur J Med Chem       Date:  2011-11-23       Impact factor: 6.514

Review 2.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

3.  Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic.

Authors:  Thommey P Thomas; Melvin Joice; Madhuresh Sumit; Justin E Silpe; Alina Kotlyar; Sophia Bharathi; Jolanta Kukowska-Latallo; James R Baker; Seok Ki Choi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Targeted dendrimer chemotherapy in an animal model for head and neck squamous cell carcinoma.

Authors:  Brent B Ward; Thomas Dunham; Istvan J Majoros; James R Baker
Journal:  J Oral Maxillofac Surg       Date:  2011-09       Impact factor: 1.895

5.  Biophysical characterization of a riboflavin-conjugated dendrimer platform for targeted drug delivery.

Authors:  Amanda B Witte; Christine M Timmer; Jeremy J Gam; Seok Ki Choi; Mark M Banaszak Holl; Bradford G Orr; James R Baker; Kumar Sinniah
Journal:  Biomacromolecules       Date:  2012-01-18       Impact factor: 6.988

6.  Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery.

Authors:  Thommey P Thomas; Seok Ki Choi; Ming-Hsin Li; Alina Kotlyar; James R Baker
Journal:  Bioorg Med Chem Lett       Date:  2010-07-08       Impact factor: 2.823

7.  Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.

Authors:  Seok Ki Choi; Thommey P Thomas; Ming-Hsin Li; Ankur Desai; Alina Kotlyar; James R Baker
Journal:  Photochem Photobiol Sci       Date:  2012-01-11       Impact factor: 3.982

8.  Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.

Authors:  Satoshi Inoue; Hui Ding; Jose Portilla-Arias; Jinwei Hu; Bindu Konda; Manabu Fujita; Andres Espinoza; Sonal Suhane; Marisa Riley; Marcus Gates; Rameshwar Patil; Manuel L Penichet; Alexander V Ljubimov; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

9.  Fiber-optic multiphoton flow cytometry in whole blood and in vivo.

Authors:  Yu-Chung Chang; Jing Yong Ye; Thommey P Thomas; Zhengyi Cao; Alina Kotlyar; Eric R Tkaczyk; James R Baker; Theodore B Norris
Journal:  J Biomed Opt       Date:  2010 Jul-Aug       Impact factor: 3.170

Review 10.  Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.

Authors:  Piper A Rawding; Jiyoon Bu; Jianxin Wang; Da Won Kim; Adam J Drelich; Youngsoo Kim; Seungpyo Hong
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.